指南与共识毛发、甲与色素性疾病

EADV毛发疾病工作组:脱发性毛囊炎的诊疗立场声明

Management of folliculitis decalvans: The EADV task force on hair diseases position statement.
指南 / 共识 · J Eur Acad Dermatol Venereol · 2025-04-14

脱发性毛囊炎是最常见的原发性中性粒细胞性瘢痕性脱发,病程慢性复发,治疗目标为控制炎症、防止进一步脱发,毛发再生不可预期。EADV毛发疾病工作组基于文献综述与专家临床经验制定诊疗推荐和治療算法,涵盖口服抗生素、糖皮质激素、异维A酸及局部治疗等分层策略。

要点

  • 中重度炎症推荐口服抗生素,高活动性疾病可短期口服糖皮质激素。
  • 轻度活动性疾病(毛囊周围红斑和角化过度、无脓疱或结痂)首选口服异维A酸。
  • 局部或皮损内糖皮质激素推荐作为全身治疗的附加治疗。

核心结论

  • 脱发性毛囊炎治疗目标为控制炎症和防止进一步脱发,毛发再生不可预期。
  • 治疗可能需延长至表现消退后以避免复发。
  • EADV毛发疾病工作组提出了诊断和治疗推荐及治疗算法。

研究设计与样本

  • EADV毛发疾病工作组立场声明。
  • 治疗算法基于文献综述和EADV毛发疾病工作组毛发疾病专家的临床经验创建。

主要发现

  • 脱发性毛囊炎是最常见的原发性中性粒细胞性瘢痕性脱发,在脱发患者中诊断率为2.8%。
  • 病程通常为慢性和复发性,可能需要多种治疗。

关键数值与推荐

  • 中重度炎症患者推荐口服抗生素。
  • 高活动性疾病患者短期口服糖皮质激素可能有益。
  • 轻度活动性疾病(毛囊周围红斑和角化过度、无脓疱或结痂)患者应考虑口服异维A酸作为一线治疗。
  • 难治性疾病或持续性炎症病变推荐异维A酸。
  • 光动力疗法、生物制剂(优选阿达木单抗)、JAK抑制剂、口服氨苯砜、羟氯喹或环孢素也可能有效。

临床怎么用

  • 根据炎症严重程度和活动性分层选择系统治疗:中重度用口服抗生素,高活动性短期用糖皮质激素,轻度活动性首选异维A酸。
  • 难治性或持续性炎症病变使用异维A酸。
  • 局部或皮损内糖皮质激素作为全身治疗附加;二线局部可选他克莫司0.1%或氨苯砜5%。
  • 手术或激光可能有用,毛发移植仅考虑用于非活动性疾病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Folliculitis decalvans is the most common form of primary neutrophilic scarring alopecia, which is diagnosed in 2.8% of patients with hair loss. The course of the disease is typically chronic and relapsing. Thus, numerous therapies may be needed. Treatment extended beyond the resolution of the manifestations may be considered to avoid recurrences. As folliculitis decalvans is a form of scarring alopecia, the aim of any therapy is to control inflammation and prevent further hair loss. Hair regrowth cannot be expected. The aim of the EADV Task Force on Hair Diseases position statement was to propose diagnostic and therapeutic recommendations for folliculitis decalvans. The therapeutic algorithm was created based on a literature review and clinical experience of the members of the EADV Task Force on Hair Diseases who are experts in hair disorders. In patients with folliculitis decalvans with moderate or severe inflammation, oral antibiotics should be recommended. In patients with highly active disease, a short course of oral glucocorticosteroids may be beneficial. Oral isotretinoin should be considered as the first-line therapy in patients with mild active disease (perifollicular erythema and hyperkeratosis, no pustules or crusts). Moreover, isotretinoin should be recommended in cases of refractory disease or persistent inflammatory lesions. Photodynamic therapy, biologics (preferably adalimumab), JAK inhibitors, oral dapsone, hydroxychloroquine or cyclosporine may also be effective. As an addition to systemic treatment, topical or intralesional corticosteroids should be recommended. Topical tacrolimus 0.1% or dapsone 5% may be considered as second-line topical therapeutic options. In patients with folliculitis decalvans, surgical excision or laser therapy can be useful. Hair transplantation can be considered in patients with inactive disease.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Waśkiel-Burnat A, Starace M, Iorizzo M, et al. Management of folliculitis decalvans: The EADV task force on hair diseases position statement. J Eur Acad Dermatol Venereol. 2025. PMID: 40230058. doi:10.1111/jdv.20687

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。